Abstract
The clinical importance of treating these patients before transplantation has been increasingly recognized, as this infection is associated with decreased patient and graft survival after renal transplantation. In accordance with the NIH Consensus Conference statement that ‘all patients with chronic hepatitis C are potential candidates for antiviral therapy’ 7 the challenge remains to identify those patients who would most benefit from antiviral therapy. 8 The hemodialysis patients who may be candidates for renal transplant should be treated according to evidence-based management of hepatitis C and affects of survival in the hemodialysis patients. 9 Interferon-based therapy is the mainstay of treatment for HCVrelated liver disease. As patients with renal dysfunction have typically been excluded from large therapeutic trials in patients with chronic hepatitis C, data on sustained virological response have been reported from small, mainly uncontrolled studies. 3,6,10
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call